IL-21, a pleiotropic cytokine exerting influence on various immune cell types including B cells, NK cells, and macrophages,24 faces challenges in its systemic administration due to dose-limiting toxicity observed in high-dose regimens during a Phase II clinical trial for IL-21 monotherapy25 in metastatic melanoma patients. This evidence concerns the gene IL21 and metastatic melanoma.